Oric Pharmaceuticals, Inc. 8-K

What Happened

• Oric Pharmaceuticals, Inc. (ORIC) filed a Form 8-K on March 31, 2026 to present a program update for rinzimetostat (ORIC-944). The update covered recently announced dose optimization data from the company's Phase 1b trial. A presentation containing the data was attached as Exhibit 99.1 and is incorporated by reference.

Key Details

• Date filed/presented: March 31, 2026.
• Drug/program: rinzimetostat (ORIC-944).
• Trial stage: Phase 1b dose optimization data were presented.
• Filing: Program presentation included as Exhibit 99.1 in the Form 8-K.

Why It Matters

• The company disclosed new clinical dose optimization data for ORIC-944, which is a material development in its clinical program. For investors, updates from Phase 1b can influence expectations about next clinical steps, development timelines, and potential upcoming milestones. The presentation is publicly available via the attached Exhibit 99.1 for those who want the detailed data.